All Industries

Top Drug Discovery Companies

252 Drug Discovery companies, sorted by total funding raised.

Aspen RxHealth

Digital health platform connecting health plans with on-demand pharmacist community for medicatio...

United StatesDigital Health, Drug Discovery
Series B·$32.0M·Jan 2021
Reverie LabsClosed

Engineering next-generation, brain-penetrant cancer therapies.

Cambridge, United States11–50Biotech, Drug Discovery
Seed·$32.0M
Sorriso Pharmaceuticals

Sorriso Pharmaceuticals is a biotechnology company advancing a pipeline of disease-modifying anti...

Sandy, United States1–10Biotech, Drug Discovery
Series A·$31.0M·Dec 2021
Converge Bio

Generative AI platform for accelerated drug discovery and molecule design serving pharma and biot...

Tel Aviv, Israel11–50Artificial Intelligence, Biotech
Series A·$30.5M·Jan 2025
Form Bio

AI-driven platform for designing and optimizing genetic medicines and genome engineering for biot...

Austin, United States11–50Artificial Intelligence, Biotech
Series A·$30.0M·Sep 2022
Great Bay Bio 大湾生物

By utilizing AI and other cutting-edge technologies, GBB aims to address the challenges of long t...

China51–200Artificial Intelligence, Biotech
Series B·$28.8M·Dec 2024
Moonwalk Biosciences

Develops precision epigenetic medicines targeting adipose biology and cardiometabolic disease usi...

South San Francisco, United States11–50Biotech, Drug Discovery
Seed·$28.5M·Jan 2024
Scioto BiosciencesAcquired

Scioto is a preclinical stage company developing innovative therapies devoted to having a transfo...

Indianapolis, United States1–10Food & Beverage, Biotech
Series B·$28.3M·Aug 2020
TwoStep Therapeutics

A versatile integrin-binding peptide, PIP

San Carlos, United States1–10Biotech, Drug Discovery
Series A·$27.6M·Jan 2026
Envisagenics

AI-driven biotechnology company discovering RNA splicing targets and developing therapeutics for ...

Long Island City, United States11–50Artificial Intelligence, Biotech
Series B·$27.4M·Jun 2024
Adimab

Provides antibody discovery and engineering services to biopharma partners using a yeast-based pl...

Lebanon, United States51–200Antibody Discovery, Biopharmaceutical
Series F·$26.0M·Jan 2012
PostEra

Medicinal Chemistry powered by Machine Learning

Boston, United States11–50Drug Discovery, Healthcare
Series A·$24.0M·Jan 2022
1910 Genetics

Make undruggable targets a thing of the past

Mountain View, United States11–50Drug Discovery, Healthcare
Series A·$22.0M·Mar 2021
Talus Bio

Discovering drugs that target the DNA regulome

Seattle, United States11–50Biotech, Drug Discovery
Venture Round·$21.7M·Aug 2024
Archon Biosciences

Biotechnology company developing AI-designed Antibody Cages (AbCs), a novel class of biologics th...

Seattle, United States11–50Biotech, Drug Discovery
Seed·$20.0M·Nov 2024
ThirtyFiveBio Limited

Biotechnology company developing first-in-class small molecule GPR35 inhibitors to treat ulcerati...

United KingdomBiotech, Drug Discovery
Bridge·$20.0M·Apr 2025
C4U CORPORATION

Medical (medical devices, drug discovery) - Middle to Growth

Osaka, JapanBiotech, Drug Discovery
Series B·$19.5M·May 2023
NOVATARG, INC.

R&D company with 3 SBIR/STTR awards from Department of Health and Human Services.

Durham, United States1–10Biotech, Drug Discovery
Grant·$18.0M·Sep 2015
Amide

Rapid robotic synthesis of valuable peptides and protein structures.

Cambridge, United States11–50Biotech, Drug Discovery
Extension Round·$16.5M·Jul 2023
General Proximity

The next generation of induced-proximity medicines.

San Francisco, United States11–50Biotech, Drug Discovery
Venture Round·$16.0M·May 2026
ACX

Next-generation biocides for sustainable agriculture at scale

New York, United States1–10Agtech, Biotech
Pre-seed·$15.5M·Oct 2024
Alternative Bio

Precision oncology biotech developing first-in-class therapeutics targeting post-translational mo...

Hong Kong, Hong Kong1–10Biotech, Healthcare
Seed·$15.0M·Dec 2022
Akari TherapeuticsIPO

Biotechnology company developing advanced therapies for autoimmune and inflammatory diseases.

London, United Kingdom1–10Antibody-Drug Conjugates, Biopharmaceutical
Venture Round·$14.6M·Dec 2025
Champions OncologyIPO

Global preclinical research and clinical specialty testing provider driving excellence in oncolog...

Hackensack, United States201–500Biotech, Drug Discovery
Corporate Round·$14.0M·Mar 2015
Parcel Biosciences

Developer of programmable mRNA delivery technology to diverse cell types in the body; next-genera...

San Francisco, United States1–10Biotech, Drug Discovery
Seed·$13.5M·May 2026